Benjamin H. Lowentritt, MD, FACS, Discusses Future Analyses for the Phase 3 SPOTLIGHT Trial in Recurrent Prostate Cancer

Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.

In an interview with CancerNetwork® during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, highlighted next steps for the phase 3 SPOTLIGHT study (NCT04186845), which examined the impact of clinical factors on detection rates of 18F-rhPSMA-7.3 in suspected recurrent prostate cancer. In terms of future analyses, Lowentritt indicated that assessing sites of disease recurrence and levels of intensity will be areas of focus.

Transcript:

The SPOTLIGHT trial data are really just coming to light and being reported. We're continuing to look at different subgroup analyses. [We are] also really drilling into some of the sites of recurrence and identifying where and when this may be most helpful. [We are] evaluating different levels of intensity, the [standardized uptake value], and other things within the actual imaging reports and how that may predict sites of disease. There is certainly continuing to be a lot of work done with the data from the SPOTLIGHT trial, which was only recently completed.

Reference

Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.